{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06360354",
            "orgStudyIdInfo": {
                "id": "20230223"
            },
            "organization": {
                "fullName": "Amgen",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion",
            "officialTitle": "A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination With Other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-evaluating-amg-in-combination-with-other-therapies-in-participants-with-advanced-gastrointestinal-biliary-tract-or-pancreatic-cancers-with-homozygous-methylthioadenosine-phosphorylase-mtap-deletion"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-05-29",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-11-28",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-11-28",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-04-08",
            "studyFirstSubmitQcDate": "2024-04-08",
            "studyFirstPostDateStruct": {
                "date": "2024-04-11",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-05",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-08",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Amgen",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety profile of AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted gastrointestinal, biliary tract, or pancreatic cancers."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers"
            ],
            "keywords": [
                "Advanced Cancer",
                "Methylthioadenosine Phosphorylase",
                "AMG 193",
                "Oncology"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 188,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Subprotocol B: Pancreatic Ductal Adenocarcinoma (PDAC) Arm A",
                    "type": "EXPERIMENTAL",
                    "description": "Part 1: Participants with MTAP-deleted PDAC will receive escalating doses of AMG 193 orally in combination with gemcitabine and nab-paclitaxel IV.\n\nPart 2: Participants with MTAP-deleted PDAC will receive the recommended dose of AMG 193 in combination with gemcitabine and nab-paclitaxel.",
                    "interventionNames": [
                        "Drug: AMG 193",
                        "Drug: Gemcitabine",
                        "Drug: Nab-paclitaxel"
                    ]
                },
                {
                    "label": "Subprotocol B: PDAC Arm B",
                    "type": "EXPERIMENTAL",
                    "description": "Part 1: Participants with MTAP-deleted PDAC will receive escalating doses of AMG 193 orally in combination with mFOLFIRINOX (irinotecan, fluorouracil, leucovorin calcium, oxaliplatin) IV.\n\nPart 2: Participants with MTAP-deleted PDAC will receive the recommended dose of AMG 193 in combination with mFOLFIRINOX.",
                    "interventionNames": [
                        "Drug: AMG 193",
                        "Drug: Modified FOLFIRINOX"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "AMG 193",
                    "description": "Administered Orally",
                    "armGroupLabels": [
                        "Subprotocol B: PDAC Arm B",
                        "Subprotocol B: Pancreatic Ductal Adenocarcinoma (PDAC) Arm A"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Gemcitabine",
                    "description": "Administered IV",
                    "armGroupLabels": [
                        "Subprotocol B: Pancreatic Ductal Adenocarcinoma (PDAC) Arm A"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Nab-paclitaxel",
                    "description": "Administered IV",
                    "armGroupLabels": [
                        "Subprotocol B: Pancreatic Ductal Adenocarcinoma (PDAC) Arm A"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Modified FOLFIRINOX",
                    "description": "Modified FOLFIRINOX consists of irinotecan, 5-FU, LV, and oxaliplatin administered IV",
                    "armGroupLabels": [
                        "Subprotocol B: PDAC Arm B"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of Participants Experiencing Dose Limiting Toxicities (DLT)",
                    "timeFrame": "Up to 28 days"
                },
                {
                    "measure": "Number of Participants Experiencing Treatment Emergent Adverse Events (TEAE)",
                    "description": "Any clinically significant changes in vital signs, electrocardiogram, or lab parameters will be recorded as TEAEs.",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Number of Participants Experiencing Serious Adverse Events (SAE)",
                    "timeFrame": "Up to approximately 2 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Objective Response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Disease Control (DC) per RECIST v1.1",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Duration of Response (DOR) per RECIST v1.1",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Time to Response (TTR) per RECIST v1.1",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Overall Survival (OS) per RECIST v1.1",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Progression-free Survival (PFS) per RECIST v1.1",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Maximum Plasma Concentration (Cmax) of AMG193",
                    "timeFrame": "Up to Day 1 of Cycle 5 (one cycle = 21 or 28 days)"
                },
                {
                    "measure": "Time to Maximum Plasma Concentration (tmax) of AMG193",
                    "timeFrame": "Up to Day 1 of Cycle 5 (one cycle = 21 or 28 days)"
                },
                {
                    "measure": "Area Under the Plasma Concentration-time Curve (AUC) of AMG 193",
                    "timeFrame": "Up to Day 1 of Cycle 5 (one cycle = 21 or 28 days)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Subprotocol B\n\nInclusion:\n\n* Age \u2265 18 years (or \u2265 legal age within the country if it is older than 18 years).\n* Histologically or cytologically confirmed diagnosis of metastatic and/or unresectable (locally advanced) adenocarcinoma of the pancreas.\n* Tumor tissue (FFPE sample) or an archival block must be available. Participants without archived tumor tissue available may be allowed to enroll by undergoing tumor biopsy before dosing.\n* Homozygous MTAP-deletion.\n* Disease measurable as defined by RECIST v1.1.\n* Adequate organ function as defined in the protocol\n\nExclusion:\n\n* Prior treatment with a MAT2A inhibitor or a PRMT5 inhibitor.\n* Radiation therapy within 28 days of first dose.\n* Major surgery within 28 days of first dose of AMG 193.\n* Cardiovascular and pulmonary exclusion criteria as defined in the protocol.\n* Gastrointestinal tract disease causing the inability to take PO medication, malabsorption syndrome, requirement for IV alimentation, gastric/jejunal tube feeds, uncontrolled inflammatory gastrointestinal disease (eg, Crohn's disease, ulcerative colitis).\n* History of solid organ transplantation.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "100 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Amgen Call Center",
                    "role": "CONTACT",
                    "phone": "866-572-6436",
                    "email": "medinfo@amgen.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "MD",
                    "affiliation": "Amgen",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Comprehensive Blood and Cancer Center",
                    "status": "RECRUITING",
                    "city": "Bakersfield",
                    "state": "California",
                    "zip": "93309",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.37329,
                        "lon": -119.01871
                    }
                },
                {
                    "facility": "City of Hope National Medical Center",
                    "status": "RECRUITING",
                    "city": "Duarte",
                    "state": "California",
                    "zip": "91010",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.13945,
                        "lon": -117.97729
                    }
                },
                {
                    "facility": "City of Hope Orange County Lennar Foundation Cancer Center",
                    "status": "RECRUITING",
                    "city": "Duarte",
                    "state": "California",
                    "zip": "91010",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.13945,
                        "lon": -117.97729
                    }
                },
                {
                    "facility": "Comprehensive Cancer Centers of Nevada",
                    "status": "RECRUITING",
                    "city": "Las Vegas",
                    "state": "Nevada",
                    "zip": "89169",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.17497,
                        "lon": -115.13722
                    }
                },
                {
                    "facility": "Cleveland Clinic",
                    "status": "RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44195",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "AmgenTrials clinical trials website",
                    "url": "http://www.amgentrials.com"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "ICF",
                "CSR"
            ],
            "timeFrame": "Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.",
            "accessCriteria": "Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.",
            "url": "http://www.amgen.com/datasharing"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000010190",
                    "term": "Pancreatic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004067",
                    "term": "Digestive System Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000004701",
                    "term": "Endocrine Gland Neoplasms"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000010182",
                    "term": "Pancreatic Diseases"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M13110",
                    "name": "Pancreatic Neoplasms",
                    "asFound": "Pancreatic Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7256",
                    "name": "Digestive System Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8886",
                    "name": "Gastrointestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7863",
                    "name": "Endocrine Gland Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M13102",
                    "name": "Pancreatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4387",
                    "name": "Pancreatic Cancer",
                    "asFound": "Pancreatic Cancer",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000017239",
                    "term": "Paclitaxel"
                },
                {
                    "id": "D000093542",
                    "term": "Gemcitabine"
                },
                {
                    "id": "C000627770",
                    "term": "Folfirinox"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000972",
                    "term": "Antineoplastic Agents, Phytogenic"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000050257",
                    "term": "Tubulin Modulators"
                },
                {
                    "id": "D000050256",
                    "term": "Antimitotic Agents"
                },
                {
                    "id": "D000050258",
                    "term": "Mitosis Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000964",
                    "term": "Antimetabolites, Antineoplastic"
                },
                {
                    "id": "D000000963",
                    "term": "Antimetabolites"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M1671",
                    "name": "Irinotecan",
                    "relevance": "LOW"
                },
                {
                    "id": "M19537",
                    "name": "Paclitaxel",
                    "asFound": "Sessions",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2985",
                    "name": "Gemcitabine",
                    "asFound": "Mg/kg",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1674",
                    "name": "Oxaliplatin",
                    "relevance": "LOW"
                },
                {
                    "id": "M8600",
                    "name": "Fluorouracil",
                    "relevance": "LOW"
                },
                {
                    "id": "M231",
                    "name": "Albumin-Bound Paclitaxel",
                    "relevance": "LOW"
                },
                {
                    "id": "M271136",
                    "name": "Folfirinox",
                    "asFound": "High Resolution",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5381",
                    "name": "Calcium",
                    "relevance": "LOW"
                },
                {
                    "id": "M5398",
                    "name": "Calcium, Dietary",
                    "relevance": "LOW"
                },
                {
                    "id": "M6191",
                    "name": "Leucovorin",
                    "relevance": "LOW"
                },
                {
                    "id": "M29233",
                    "name": "Levoleucovorin",
                    "relevance": "LOW"
                },
                {
                    "id": "M26197",
                    "name": "Tubulin Modulators",
                    "relevance": "LOW"
                },
                {
                    "id": "M26196",
                    "name": "Antimitotic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4281",
                    "name": "Antimetabolites",
                    "relevance": "LOW"
                },
                {
                    "id": "T447",
                    "name": "Folinic Acid",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "BDCA",
                    "name": "Bone Density Conservation Agents"
                },
                {
                    "abbrev": "Micro",
                    "name": "Micronutrients"
                },
                {
                    "abbrev": "Vi",
                    "name": "Vitamins"
                }
            ]
        }
    },
    "hasResults": false
}